



New Jersey Bioscience Center Newsletter

FIRST QUARTER 2022

New Jersey Bioscience Center In The News

Bristol Myers, VCs Launch New RNA Therapeutics - Ceptur with \$75M A Round

Headquartered in Hillsborough NJ, Ceptur is a pre-clinical stage company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology. With technology in-licensed from Rutgers University, the company is pioneering a new wave of oligonucleotide-based genetic medicines through partnership of foundational leadership team with world-renowned Scientific Advisory Board. [Link for more information](#) about Ceptur Therapeutics.

NJ ranked fourth among the states in GDP growth

NJ ranked fourth among the states in GDP growth for the 3rd Q of 2021. The article also gives a good overview of the positives underway in the state's economy.

34 Best New Jersey Clinical Trials Companies and Startups -

According to BESTSTARTUP.US, this article showcases top picks for the best New Jersey based Clinical Trials companies.



NEW JERSEY BIOSCIENCE CENTER

675 US-1, North Brunswick
Township, NJ 08902

[BioAegis Therapeutics Highlights 2021 Accomplishments](#)

BioAegis Therapeutics Inc., a clinical-stage company developing therapies for infectious, inflammatory, and degenerative diseases reported highlights from its recent shareholder meeting.

Highlights Include:

- Completed 2nd clinical study in the EU & planning US phase 2/3 program in critical care.
- Launched a Series C round and completed the 1st closing with a European VC.
- Secured a [BARDA contract](#) to further develop the Company's novel host-directed therapy for the critically ill sepsis patient population.
- Completed third manufacturing campaign in preparation for scaled-up GMP production of clinical supplies
- The Company filed additional patents to add to the over 40 patents issued for coverage in inflammatory disease, infection, renal failure, and neurologic disease.

BioAegis is a current resident of the Step-Out Labs and a graduate of the Incubator at North Brunswick.

[Bright Cloud International In Partnership with SAM Group](#)

Incubator at North Brunswick resident, Bright Cloud International, launched a Partnership with SAM Group that will help the Rutgers University spin-off bring its tele-rehab medical devices to a larger customer base. Bright Cloud leveraged resources at our Incubator at North Brunswick to fuel its growth!

[Genomic Prediction Team Expands Operations Within Our Research Park](#)

Genomic Prediction, a soon-to-be-graduate of the Incubator at North Brunswick, is doubling the size of their operations within the New Jersey Bioscience Center research park. The company expects to move out of the Incubator at North Brunswick and into their new 7000 SF lab and office facility in February. An overview of the Genomic Prediction operations can be [viewed in this amazing new video](#).

[Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial](#)

Step-Out Labs resident, Adlai Nortye, a clinical-stage biopharmaceutical company focused in oncology, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to evaluate the safety, tolerability, PK and preliminary efficacy of the orally available, small-molecule PD-L1 inhibitor AN4005 in patients with advanced tumors. "Adlai Nortye aspires to develop differentiated cancer immunotherapy medicines for global markets. The Company's "cocktail" therapy strategy represents the third wave of uno-oncology therapy", said Dr. Lars Birgerson, CMO of Adlai Nortye, and CEO of Adlai Nortye USA.

[Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index](#)

Step-Out Labs resident, Oyster Point Pharma, is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies to treat ocular surface diseases. The company recently announced that it will be added to the **Nasdaq Biotechnology Index** (Nasdaq: NBI). The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

[Incubator at North Brunswick has a new Resident, Welcome Osseoprint 3D!](#)

[Osseoprint 3D](#) has developed a proprietary platform to design and 3D print patient-matched bone scaffolds for fast and simple bone reconstruction surgeries. Orthopedic, dental, cosmetic, and other surgeons can augment and reconstruct bone defects with precision, speed, and safety with this chair-side 3D printing technology. The Osseoprint team is in Lab 132.



New Jersey Bioscience Center Newsletter

FIRST QUARTER 2022

[New Jersey Center of Excellence at Bridgewater](#)

The R&D campus encompasses over 850,000 SF of laboratory, office, GMP production and warehouse facilities and includes a full-service cafeteria, fitness, and conference center. The Center of Excellence provides a full range of modern lab facilities.

[Princeton Corporate Plaza](#)

Located in Monmouth Junction, Princeton Corporate Plaza has fully furnished laboratory space for any size company. "We are one of New Jersey's most successful laboratory facilities, hosting a wide range of scientific research and development companies both large and small. Our Research Center is home to over 80 scientific companies including: Cytosorbents, Pharmaseq, Rive Technology, TyRx Pharma, Alliance Technologies, Signum Biosciences, United Silicon Carbide, Taxis Pharmaceuticals, Palatin Technologies, American Cryo-stem and Klus".

[Availability at the New Jersey Bioscience Center Research Park](#)

The Incubator has one large lab available now. Small labs will be available soon. [Email](#) or call Lenzie with any questions.



NEW JERSEY BIOSCIENCE CENTER

675 US-1, North Brunswick Township, NJ 08902

New Jersey Bioscience Center Alumni News

[Amicus Publishes Pivotal Phase 3 PROPEL Study Results](#)

Incubator at North Brunswick graduate, [Amicus Therapeutics](#) (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, recently announced that the data from its Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of care, alglucosidase alfa. The results were published online in [The Lancet Neurology](#).

[Brooks Automation ReBrands Genewiz as Azenta Life Sciences](#)

Incubator at North Brunswick graduate, Genewiz, was purchased by Brooks Automation in 2018. Recently, Brooks Automation announced Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – *Azenta Life Sciences*. In 2002, Genewiz was launched at the Incubator at North Brunswick (formerly CCIT) by Columbia University post-doctoral researchers Dr. Steve Sun and Dr. Amy Liao.

[PDS Announces Preclinical Data for PDS0202 Universal Influenza Vaccine](#)

Due to the existence of multiple strains of flu, a new seasonal flu vaccination is usually developed to provide protection against the strains predicted to be prevalent in an upcoming flu season. As a result, the protective efficacy of the current vaccines varies widely from season to season. PDS Biotechnology is developing a new generation of flu vaccines with the potential to provide long-lasting, and broad protection against multiple strains of the virus. In [addition, PDS recently signed](#) a license agreement for Computationally Optimized Broadly Reactive Antigen (COBRA) antigens from the University of Georgia to use in the clinical development of PDS0202, the company's universal flu vaccine candidate. PDS is a graduate of the Incubator at North Brunswick.

[Orthobond Appoints Frank Cammisa, MD as Chief Medical Officer](#)

Renowned Spine Surgeon Joins Advisory Team for Orthobond – Orthobond, a graduate of the Incubator at North Brunswick, is a leader in covalently-bound antimicrobial surface treatments with broad applications in the medical device industry announced the appointment of Frank P. Cammisa, MD, as the company's Chief Medical Officer. In this role Dr. Cammisa will provide leadership in clinical research and commercial applications for the technology.

[Life Sciences Real Estate News in New Jersey](#)

[Princeton West Innovation Campus Announcements](#)

In November, BeiGene, a Chinese global biotech firm focused on commercializing cancer treatments, purchased a 42-acre portion of its Princeton Innovation Campus. BeiGene, headquartered in Beijing, plans to make a major investment in the site, which will include 400,000 SF of pharmaceutical manufacturing along with clinical research facilities, to diversify its global supply chain. It is expected to finish renovations in 2024. Princeton West Innovation Campus is a multi-tenant research park on a 433-acre former BMS site with over 30 buildings.

[Cedar Brook Corporate Center 150 Acre Life Sciences Campus](#)

According to the website, Cedar Brook "offers an ideal work environment for science and technology minded companies." Located on Route 130 at Exit 8A, the site is situated on 150 acres with a 10-acre lake and walking paths. The biopharma tenant list includes Amicus Therapeutics, Cornerstone Pharmaceuticals and Endo Pharmaceuticals.

[Demand for Lab Space Far Exceeds Supply in NJ](#)

Demand for new life sciences lab space is far outpacing speculative construction in New Jersey, with biomanufacturing tenants looking for approximately 800,000 square feet of space in the market to meet rapid growth amid a global race for new drug development, according to a new report from CBRE. "New Jersey is a hotbed for the life sciences sector with strong VC funding, record job growth and demand for lab space outpacing supply by a large margin," said Thomas Sullivan, senior vice president, CBRE. "Given New Jersey's position as one of the country's top markets for R&D employment growth over the past year, demand for space will remain extremely high and owners will have to adapt and create the type of properties needed to support this need."